Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial
Author(s) -
Rami Kantor,
Laura Smeaton,
Saran Vardhanabhuti,
Sarah E. Hudelson,
Carole L. Wallis,
Srikanth Tripathy,
Mariza Gonçalves Morgado,
Shanmugam Saravanan,
Pachamuthu Balakrishnan,
Marissa B Reitsma,
Stephen A. Hart,
John W. Mellors,
Elias K. Halvas,
Beatriz Grinsztejn,
Mina C. Hosseinipour,
Johnstone Kumwenda,
Alberto La Rosa,
Umesh Lalloo,
Javier R. Lama,
Mohammed Rassool,
Breno Santos,
Khuanchai Supparatpinyo,
James Hakim,
Timothy Flanigan,
Nagalingeswaran Kumarasamy,
Thomas Campbell,
Susan H. Eshleman
Publication year - 2015
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/civ102
Subject(s) - medicine , hazard ratio , hiv drug resistance , viral load , genotyping , proportional hazards model , confidence interval , drug resistance , human immunodeficiency virus (hiv) , genotype , immunology , gastroenterology , antiretroviral therapy , biochemistry , biology , microbiology and biotechnology , gene , chemistry
Evaluation of pretreatment HIV genotyping is needed globally to guide treatment programs. We examined the association of pretreatment (baseline) drug resistance and subtype with virologic failure in a multinational, randomized clinical trial that evaluated 3 antiretroviral treatment (ART) regimens and included resource-limited setting sites.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom